Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study

Osteoarthritis and Cartilage

Volumn 15, Issue 4, 2007, Pages 386-395

  Papaioannou, N A ^a   Triantafillopoulos, I K ^a   Khaldi, L ^a,b   Krallis, N ^a   Galanos, A ^a   Lyritis, G P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Animal studies; Anterior cruciate ligament Transection; Calcitonin; Histology; Osteoarthritis

Indexed keywords

ALCIAN BLUE; PLACEBO; SALCATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; HYALINE CARTILAGE; KNEE CRUCIATE LIGAMENT; KNEE INSTABILITY; MALE; MORPHOMETRICS; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; REGENERATION; ULCER;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CARTILAGE; HUMANS; OSTEOARTHRITIS; RABBITS;

EID: 33847724808     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.10.012     Document Type: Article

References (43)

1. Felson D.T., Lawrence R.C., Hochberg M.C., McAlindon T., Dieppe P.A., Minor M.A., et al. Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med 133 (2000) 726-737
2. Walker-Bone K., Javaid K., Arden N., and Cooper C. Regular review: medical management of osteoarthritis. BMJ 321 (2000) 936-940
3. Brandt K.D., and Bradley J.D. Should the initial drug be used to treat osteoarthritis pain be a non-steroidal anti-inflammatory drug?. J Rheumatol 28 (2001) 467-473
4. Felson D.T. The verdict favors non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis and a plea for more evidence on the other treatments. Arthritis Rheum 44 (2001) 1477-1480
5. Abramson S.B. The role of NSAIDs in the treatment of osteoarthritis. In: Brandt K.D., Doherty M., and Lohmander L.S. (Eds). Osteoarthritis (2003), Oxford University Press 251-258
6. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., and Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 9450 (2004) 2021-2029
7. McAlindon. Nutritional therapies. In: Brandt K.D., Doherty M., and Lohmander L.S. (Eds). Osteoarthritis (2003), Oxford University Press 289-292
8. Mroz P.J., and Silbert J.E. Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum 50 (2004) 3574-3579
9. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M., et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the condromodulating effect of diacerein in OA of the hip. Arthritis Rheum 44 (2001) 2539-2547
10. Knutson K. Arthroplasty and its complications. In: Brandt K.D., Doherty M., and Lohmander L.S. (Eds). Osteoarthritis (2003), Oxford University Press 361-370
11. Tanko L.B., Bagger Y.Z., Alexandersen P., Devogelaer J.P., Reginster J.Y., Chick R., et al. Safety and efficacy of a novel salmon calcitonin (SCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19 (2004) 1531-1538
12. Pun K.K., and Chan L.W. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11 (1989) 205-209
13. Badurski J., Jeziernicka E., Naruszewicz K., and Racewicz A. Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analog scale (VAS). Pol Tyg Lek 50 (1995) 37-40
14. Manicourt D.H., Altman R., Williams J.M., Van Egeren A., Lenz M.E., Petrela D., et al. Treatment with calcitonin suppresses the response of bone, cartilage and synovium in the prophylactic stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 42 (1999) 1159-1167
15. Behets C., Williams J.M., Chappard D., Devogelaer J.P., and Manicourt D.H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 19 (2004) 1821-1826
16. Yoshioka M., Coutts R.D., Amiel D., and Hacker S.A. Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 4 2 (1996) 87-98
17. Bendele A.M. Animal models for osteoarthritis. J Musculoskel Neuron Interact 1 14 (2001) 363-376
18. Mankin H.J., Dorfman H., Lippiello L., and Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am 53 3 (1971) 523-537
19. Radin E.L., and Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 213 (1986) 34-40
20. El Hajjaji H., Williams J.M., Devogelaer J.P., Lenz M.E., Thonar E.J., and Manicourt D.H. Treatment with calcitonin prevents the net loss of collagen, hyluronan and proteoglycan aggregates from cartilage in the prophylactic stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 904-911
21. Azria M., and Avioli L.V. Calcitonin. In: Bilezikian J.P., Raiz L.G., and Rodan G.A. (Eds). Principles of Bone Biology (1996), Academic Press, San Diego 1083-1097
22. Aida S., Okawa-Takatsuji M., Aotsuka S., Shimoji K., and Yokohari R. Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis. Ann Rheum Dis 53 (1994) 247-249
23. Sileghem A., Geusens P., and Dequeker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 51 (1992) 761-764
24. Siamopoulos A., Challa A., Kapoglou V., Cholevas V., Mavridis A.K., and Lapatsanis P.D. Effects of intranasal salmon calcitonin in juvenile idiopathic arthritis: an observational study. Calcif Tissue Int 69 (2001) 25-30
25. Havelka S., and Hurych J. In vitro effects of calcitonin on inflammation. Horn Metab Res 12 (1980) 226-227
26. Strettle R.J., Bates R.F., and Buckley G.A. Evidence for a direct anti-inflammatory action of calcitonin: inhibition of histamine-induced mouse pinnal oedema by porcine calcitonin. J Pharm Pharmacol 32 (1980) 192-195
27. Hellio M.P., Pescard M.J., Cohen C., Richard M., and Vignon E. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthritis Cartilage 5 (1997) 121-128
28. Burr D.B. Subchondral bone in the pathogenesis of osteoarthritis. Mechanical aspects. In: Brandt K.D., Doherty M., and Lohmander L.S. (Eds). Osteoarthritis (2003), Oxford University Press 125-133
29. Fornasier V.L., Stapleton K., and Williams C.C. Histologic changes in Paget's disease treated with calcitonin. Hum Pathol 9 (1978) 455-461
30. Mongiorgi R., Maggi G., Bertocchi G., Moroni A., Rollo G., Gnudi S., et al. Influence of calcitonin treatment on the bone structure and mineral content in osteoarthritis. Boll Soc Ital Biol Sper 68 (1992) 85-89
31. Mosekilde L., Danielsen C.C., and Gasser J. The effect on vertebral bone mass and strength of long-term treatment with anti-resorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 134 (1994) 2126-2134
32. Geusens P., Boonen S., Nijs J., Jiang Y., Lowet G., Van Auderkerke R., et al. Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 59 (1996) 315-320
33. Franchimont P., Bassleer C., Henrotin Y., Gysen P., and Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab 69 (1989) 259-266
34. Baca S., Altman R.D., and Dean D.D. Calcitonin effects on rabbit articular cartilage explants. J Bone Miner Res 7 Suppl 1 (1992) S254
35. Badurski J.E., Schwamm W., Popko J., Zimmoch L., Rogowski F., and Pawlica J. Chondroprotective action of salmon calcitonin in experimental arthropathies. Calcif Tissue Int 49 (1991) 27-34
36. Papaioannou N.A., Krallis N., Triantafillopoulos I.K., Khaldi L., Dontas I., and Lyritis G.P. Optimal timing of research after anterior cruciate ligament resection in rabbits. Contemp Top Lab Anim Sci 43 6 (2004) 22-27
37. Xerogeanes J.W., Fox R.J., Takeda Y., Kim H.S., Ishibashi V., Carling G.J., et al. A functional comparison of animal anterior cruciate ligament models to the human anterior cruciate ligament. Ann Biomed Eng 26 3 (1998) 345-352
38. Badurski J., Popko J., Zimnoch L., and Nariszewicz K. Anabolic effects of salmon calcitonin on rat and mice joint cartilage. Bone 18 Suppl 1 (1995) S174
39. Pond M.J., and Nuki G. Experimentally induced osteoarthritis in the dog. Ann Rheum Dis 32 (1973) 387-388
40. Marshall K.W., and Chan A.D. Arthroscopic anterior cruciate ligament transection induces canine osteoarthritis. J Rheumatol 23 (1996) 338-343
41. Visco D.M., Hill M.A., and Widmer W.R. Experimental osteoarthritis in dogs: a comparison of the Pond-Nuki and medial arthrotomy methods. Osteoarthritis Cartilage 4 (1996) 9-22
42. Azangwe G., Mathias K.J., and Marshall D. The effect of flexion angle on the macro and microscopic appearance of the rupture surface of the ACL of rabbits. Knee 8 1 (2001) 29-37
43. Woo S.L.Y., Hollis R.D., Roux R.D., Gomez M.A., Inoue M., Kleiner J.B., et al. Effects of flexion angle on the structural properties of the rabbit femur-anterior cruciate ligament-tibia complex (FATC). J Biomech 20 (1987) 557-563